Sanofi has entered into a definitive agreement to acquire ownership of Qunol, a US-based, market-leading brand in health and wellness.
This transaction will strengthen Sanofi’s Consumer Healthcare’s (CHC) Vitamin, Mineral and Supplements (VMS) category, one of the largest and fastest-growing consumer health categories in the US, focusing on the active ‘healthy ageing’ segment.
With Qunol’s CoQ10 in heart health and turmeric in joint health, CHC at Sanofi adds a trusted, profitable double-digit growth brand to its US portfolio, focused on chronic conditions with growing consumer demand. With this acquisition, Sanofi continues to pursue growth opportunities and value creation for its consumer healthcare business.
Julie Van Ongevalle, Executive Vice President, Consumer Healthcare, Sanofi: “The acquisition of Qunol further strengthens our portfolio in the wellness category. It taps into the growing ‘healthy ageing’ segment and fills one of our white spaces in the US, unlocking an opportunity for us to build on our US presence and accelerate our growth."
Van Ongevalle: "VMS now functions as long-term support for overall health and wellness where proactive preventive health has become the new norm post-pandemic. We are excited to welcome Qunol and, with this addition to our consumer healthcare portfolio, reinforce our commitment to bring more health into the hands of people.”
Qunol CoQ10 and turmeric products are both backed by science literature and strong market positioning in their segments. Qunol’s high product quality and efficacy have resulted in strong brand equity among consumers and customers, as well as above category consumer loyalty. The Qunol brand will benefit from Sanofi’s CHC resources to expand into other chronic conditions and develop its footprint outside the US.
Peter Boutros, CEO, Quten Research Institute, said: “Qunol is looking forward to joining Sanofi’s consumer healthcare team and developing synergies that will further drive brand awareness for our products with our consumers and customers. With Sanofi, we have the opportunity to further grow in the U.S. and beyond, tapping into Sanofi Consumer Healthcare’s commercial breadth and strength.”
Sanofi entered into a definitive agreement to acquire ownership of Qunol, subject to customary closing conditions, including applicable regulatory approvals. The acquisition is expected to close Q3 2023.
